News by Subject Chemistry & Physics

Researchers at the University of Copenhagen have developed a prototype of an app that may potentially prescribe the optimal dose of medicine for the individual patient, as well as prevent counterfeit products.

Targeting specific areas of the measles virus polymerase, a protein complex that copies the viral genome, can effectively fight the measles virus and be used as an approach to developing new antiviral drugs to treat the serious infectious disease, according to a study by the Institute for Biomedical Sciences at Georgia State University published in PLoS Pathogens.

First head-to-head comparison of CDK4/6 inhibitors in cell line and animal models of breast cancer reveals important differences, including one drug that exhibits unique, potentially advantageous therapeutic activity.

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the development of an agent against the metastasis of certain cancers. Using the Swiss Light Source, they deciphered the structure of a receptor that plays a crucial role in the migration of cancer cells.

New research finds that fish oil supplements have no effect on type 2 diabetes. Increased consumption of omega 3 fats is widely promoted globally because of a common belief that it will protect against, or even reverse, conditions such as diabetes. But a systematic review commissioned by the World Health Organization, to be published in the British Medical Journal, finds that omega 3 supplements offer no benefit.

Mount Sinai researchers have found a new type of therapy to be effective for patients with a particular type of bone marrow cancer that is resistant to several standard therapies, according to results of a clinical trial published in The New England Journal of Medicine in August.

Like many women who develop a particular type of breast cancer, the same gene -- HER2 -- also appears to be the cause of lung cancer in many dogs. TGen and Ohio State found that neratinib -- a drug that has successfully been used to battle human breast cancer -- might also work for many of the nearly 40,000 dogs in the US that annually develop the most common type of canine lung cancer, known as CPAC.